PharmSource – Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 Edition

This report characterizes the contract small molecule active pharmaceutical ingredient (API) manufacturing industry through a number of quantitative dimensions, including number and type of participants, containment and controlled substance capabilities, and financial performance of the top public contract manufacturing organizations (CMOs). Contract Small Molecule API Manufacturing is critical for establishing an understanding of the small molecule API CMO industry and the features of some of the largest CMOs participating in the industry.

Scope

Who should buy this report?

This 44-page report gives important, expert insight you won’t find in any other source. 26 tables and figures throughout the report illustrate major points and trends. This report is required reading for:

• CMO executives who must have deep understanding of the small molecule API marketplace to make strategic planning and investment decisions.

• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

Overview of contract small molecule API facilities and the proportion of containment and controlled substance specialist capabilities

Detailed view of the geographic distribution of the small molecule API facilities

Establishing which CMOs are most involved in contract small molecule API industry by facility count

Analysis of M&A activity related to small molecule API facilities

Companies mentioned

Aarti Drugs Ltd

Aarti Industries Ltd

Abbott Laboratories

AbbVie Inc

Acacia Life Sciences Pvt Ltd

Aceto Corp

Advent International Corp

Agilent Technologies Inc

Ajinomoto Co Inc

Akzo Nobel NV

Albany Molecular Research Inc

Albemarle Corp

Alcami Corp

Alembic Pharmaceuticals Ltd

Alkali Metals Ltd

Alkem Laboratories Ltd

Allergan Plc

Altasciences

AMAG Pharmaceuticals Inc

Amgen Inc

AMPAC Fine Chemicals LLC

Amphastar Pharmaceuticals Inc

Antibiotice SA

Anuh Pharma Ltd

Apeloa Co Ltd

Apiscent Labs LLC

Aptuit LLC

Arc Trinova Ltd

Arch Pharmalabs Ltd

Arkema SA

Aspen Pharmacare Holdings Ltd

Astellas Pharma Inc

AstraZeneca Plc

Audax Private Equity

Auro Laboratories Ltd

Aurobindo Pharma Ltd

Avara Pharmaceutical Services Inc

Avista Pharma Solutions Inc

Bachem Holding AG

Bain Capital Private Equity, LP

Bajaj Healthcare Ltd

BASF SE

Bausch Health Companies Inc

Baxter International Inc

Bayer AG

Beximco Pharmaceuticals Ltd

BGF Investments LP

Biocon Ltd

Biotika AS

Bristol-Myers Squibb Co

C² PHARMA S.à r.l

Cadila Healthcare Ltd

Cambrex Corp

Catalent Inc

Centrient Pharmaceuticals

Changzhou Qianhong Bio-Pharma Co Ltd

Chunghwa Chemical Synthesis & Biotech Co Ltd

Church & Dwight Co Inc

Cipla Ltd

CKD Bio Corp

Companhia Industrial Produtora de Antibioticos SA

Cook Pharmica LLC

Corbion NV

CordenPharma International

Covance Inc

CVC Capital Partners Fund VI

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Daito Pharmaceutical Co Ltd

Dawnrays Pharmaceutical (Holdings) Ltd

Deva Holding AS

Divi's Laboratories Ltd

Dr. Reddy's Laboratories Ltd

Edgewater Capital Partners

Eisai Co Ltd

Eli Lilly and Co

Ercros SA

EstechPharma Co Ltd

Everest Organics Ltd

Everlight Chemical Industrial Corp

Evonik Industries AG

Evotec AG

F. Hoffmann-La Roche Ltd

Fareva SA

FDC Ltd

Formosa Laboratories Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Granules India Ltd

H. Lundbeck AS

Hainan Shuangcheng Pharmaceuticals Co Ltd

Halo Pharma Inc

Hanmi Pharmaceuticals Co Ltd

High Tech Pharm Co Ltd

Hikal Ltd

Hikma Pharmaceuticals Plc

Huadong Medicine Co Ltd

IDT Australia Ltd

Inabata & Co Ltd

Indoco Remedies Ltd

Ind-Swift Laboratories Ltd

Insys Therapeutics Inc

International Isotopes Inc

IOL Chemicals and Pharmaceuticals Ltd

IPCA Laboratories Ltd

Ipsen SA

J B Chemicals and Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd

Jazz Pharmaceuticals Plc

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Lianhuan Pharmaceutical Co Ltd

Jiangxi Fushine Pharmaceutical Co Ltd

Jiangxi Synergy Pharmaceutical Co Ltd

Johnson & Johnson

Johnson Matthey Plc

Kaneka Corp

Kemwell Biopharma Pvt Ltd

Kingchem Life Science LLC

Krebs Biochemicals & Industries Ltd

Kyowa Hakko Kirin Co Ltd

Laboratorios Farmaceuticos Rovi SA

Lannett Company Inc

Laurus Labs Ltd

LG Chem Ltd

Lianhe Chemical Technology Co Ltd

Livzon Pharmaceutical Group Co Ltd

Lonza Group Ltd

Lupin Ltd

MallInckrodt Plc

Mercachem-Syncom Group

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

MilliporeSigma

Minakem SAS

Mitsubishi Tanabe Pharma Corp

Morepen Laboratories Ltd

Motilal Oswal Private Equity Advisors Private Limited; Rosewood Private Investments

Mylan NV

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Nantong Jinghua Pharmaceutical Co Ltd

Natco Pharma Ltd

Nectar Lifesciences Ltd

Nektar Therapeutics

Neuland Laboratories Ltd

Nippon Fine Chemical Co Ltd

Nissan Chemical Corp

Noramco

North China Pharmaceutical Co Ltd

Northeast Pharmaceutical Group Co Ltd

Novartis AG

Novo Nordisk AS

Olon SpA

Orchid Pharma Ltd

Otsuka Holdings Co Ltd

Parabolic Drugs Ltd

Patheon NV

PCAS

Permira

Perrigo Co Plc

Pfizer Inc

PharmaCore Inc

Pharmaron Beijing Co Ltd

Piramal Enterprises Ltd

Pisgah Labs Inc

Porton Pharma Solutions Ltd

Punjab Chemicals & Crop Protection Ltd

Purdue Pharma LP

Recipharm AB

Reckitt Benckiser Group Plc

Recordati SpA

Recro Pharma Inc

Richter Gedeon Nyrt

Royal DSM NV

SAI Life Sciences Ltd

Sandoz GmbH

Sanochemia Pharmazeutika AG

Sanofi

Savior Lifetec Corp

SCI Pharmtech Inc

ScinoPharm Taiwan Ltd

SeQuent Scientific Ltd

Seven Star Pharmaceutical Co Ltd

Shandong Xinhua Pharmaceutical Co Ltd

Sharon Bio-Medicine Ltd

Shenzhen Hepalink Pharmaceutical Group Co Ltd

Shilpa Medicare Ltd

Shionogi & Co Ltd

SI Group Inc

Siegfried Holding AG

SK Biotek Co Ltd

SK Capital Partners

Smruthi Organics Ltd

SMS Pharmaceuticals Ltd

Solara Active Pharma Sciences Ltd

Solvay SA

Sopharma AD

ST Pharm Co Ltd

Standard Chem & Pharm Co Ltd

Sterling Pharma Solutions Ltd

Strides Pharma Science Ltd

Sumitomo Chemical Co Ltd

Sun Pharmaceutical Industries Ltd

Suven Life Sciences Ltd

Syncom BV

Syngene International Ltd

Synmosa Biopharma Corp

Takeda Pharmaceutical Co Ltd

Tasmanian Alkaloids Pty Ltd

Terumo Corp

Teva Pharmaceutical Industries Ltd

The Carlyle Group

Tokuyama Corp

Torrent Pharmaceuticals Ltd

TPG Capital LP

TPI Enterprises

Tyche Industries Ltd

Ube Industries Ltd

UCB SA

Umicore NV

Unichem Laboratories Ltd

UniTao Pharmaceuticals LLC

Vistin Pharma AS

Wacker Chemie AG

Wanbury Ltd

Yakult Honsha Co Ltd

Yuki Gosei Kogyo Co Ltd

Yung Zip Chemical Ind Co Ltd

Zentiva Group as

Zhejiang Cheng Yi Pharmaceutical Co Ltd

Zhejiang Hisoar Pharmaceutical Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Zhejiang Huahai Pharmaceutical Co Ltd

Zhejiang Jingxin Pharmaceutical Co Ltd

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Zhejiang Medicine Co Ltd

Zhejiang Starry Pharmaceutical Co Ltd

Zhejiang Tianyu Pharmaceutical Co Ltd

Zhejiang Xianju Pharmaceutical Co Ltd

Zhejiang Yongtai Technology Co Ltd

Table of Contents

1 Table of Contents

2 List of Tables

3 List of Figures

4 Executive Summary

5 Industry Size and Structure

5.1 Definition of the Small Molecule API CMO Universe

5.2 Industry Demographics

6 Top CMOs by Small Molecule API Facilities

6.1 Controlled Substance Small Molecule API Manufacturing Facilities

6.2 Small Molecule API Manufacturing Facilities with Containment

7 Geographical Distribution of Small Molecule Manufacturing Facilities

7.1 Geographical Distribution of Controlled Substance Facilities

7.2 Geographical Distribution of Facilities with Containment Capabilities

7.3 European Analysis

8 Characteristics of the Largest CMOs

9 M&A Activity Involving Small Molecule Contract Manufacturing Facilities

10 The Outlook for the API CMO Industry

11 Notes on Methodology

12 Appendix

12.1 Appendix Tables

12.2 Bibliography

12.3 Primary Research – Key Opinion Leaders in this Report

12.4 About the Authors

12.5 Contact Us

12.6 Disclaimer

List of Tables

Table 1: Revenue Composition and Specialized Capabilities of Leading CMOs, 2018 25

Table 2: Percentage of Companies by Revenue Tier with Specialized Capabilities (Dedicated Contract and Public CMOs Only)

Table 3: CMO Small Molecule API Manufacturing Facility Acquisitions, 2015–2018 30

Table 4: CMO Small Molecule API Manufacturing Facilities Acquired by Company M&A and Divestment, 2015–2018 30

Table 5: CMO Small Molecule API Manufacturing Facilities Acquired by PE, 2015–2018 31

Table 6: Geographic Reach of CMOs with Small Molecule API Manufacturing, 2018 35

Table 7: Public CMOs’ API Manufacturing Facilities and Controlled Substance/Containment Capabilities, 2018 40

List of Figures

Figure 1: Geographic Reach of the Small Molecule API CMO Universe, 2018 (Public CMOs Only) 7

Figure 2: Public CMOs with Small Molecule Manufacturing Capability by Annual Contract Revenue, 2018 8

Figure 3: Geographic Distribution by Headquarters of Public Small Molecule API Dedicated Contract CMOs 9

Figure 4: Top CMOs by Small Molecule API Manufacturing Facilities 10

Figure 5: Top CMOs by Small Molecule API Facilities with Containment Capabilities 11

Figure 6: Top CMOs by Small Molecule API Facilities with Controlled Substance Capabilities 12

Figure 7: Oncology Pipeline by Developmental Stage and Molecule Type 14

Figure 8: Geographical Distribution of All CMO Small Molecule API Manufacturing Facilities 15

Figure 9: Geographical Distribution of Controlled Substance Small Molecule Manufacturing Facilities 17

Figure 10: Geographical Distribution of Small Molecule Manufacturing Facilities with Containment Capabilities 19

Figure 11: NMEs Requiring Special Handling, 2008–2018 20

Figure 12: Geographical Distribution of Small Molecule Contract Manufacturing Facilities in Europe, 2018 21

Figure 13: Distribution of European Small Molecule Contract Manufacturing Facilities with Containment Capabilities, 2018 22

Figure 14: Distribution of Controlled Substance European Small Molecule Contract Manufacturing Facilities, 2018 22

Figure 15: Public CMOs with Small Molecule Manufacturing Capability by Accumulated Contract Revenue, 2018 24

Figure 16: CMO Small Molecule API Manufacturing Facility with Containment Acquisitions, 2015–2018 27

Figure 17: Controlled Substance CMO Small Molecule API Manufacturing Facility Acquisitions, 2015–2018 27

Figure 18: All M&A Deals Involving Small Molecule API Containment Facilities, by Most Active CMOs, 2015–2018 28

Figure 19: All M&A Deals Involving Small Molecule API Controlled Substance Facilities, by Most Active CMOs, 2015–2018 29

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports